Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Down 16.1% in October

Gyre Therapeutics, Inc. (NASDAQ:GYRE) was the target of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 376,600 shares, a decrease of 16.1% from the October 15th total of 448,700 shares. Based on an average daily volume of 48,100 shares, the short-interest ratio is currently 7.8 days. Currently, 1.6% of the shares of the stock are sold short.

Gyre Therapeutics Stock Performance

Gyre Therapeutics stock opened at $13.12 on Friday. Gyre Therapeutics has a 1 year low of $8.26 and a 1 year high of $30.40. The firm’s 50 day moving average price is $13.83 and its two-hundred day moving average price is $13.00.

Gyre Therapeutics (NASDAQ:GYRE) last posted its quarterly earnings data on Tuesday, August 13th. The company reported $0.01 earnings per share for the quarter. The firm had revenue of $25.23 million for the quarter. Gyre Therapeutics had a negative net margin of 60.75% and a negative return on equity of 119.54%. Equities research analysts forecast that Gyre Therapeutics will post -0.45 earnings per share for the current year.

Hedge Funds Weigh In On Gyre Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC lifted its position in shares of Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares in the last quarter. State Street Corp increased its stake in Gyre Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after buying an additional 8,412 shares during the period. FMR LLC purchased a new stake in Gyre Therapeutics in the 3rd quarter worth approximately $47,000. Advantage Alpha Capital Partners LP acquired a new stake in shares of Gyre Therapeutics during the 3rd quarter valued at $334,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after acquiring an additional 90,557 shares in the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.